Maccura Biotechnology Co.Ltd (300463.SZ)
CNY 12.06
(0.08%)
CNY 12.06
(0.08%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.5 Billion CNY | -7.62% |
| 2022 | 1.63 Billion CNY | -19.4% |
| 2021 | 2.02 Billion CNY | -14.17% |
| 2020 | 2.35 Billion CNY | 8.77% |
| 2019 | 2.16 Billion CNY | 28.24% |
| 2018 | 1.69 Billion CNY | 74.36% |
| 2017 | 970.12 Million CNY | 133.76% |
| 2016 | 415 Million CNY | 11.65% |
| 2015 | 371.71 Million CNY | -12.39% |
| 2014 | 424.27 Million CNY | 82.46% |
| 2013 | 232.53 Million CNY | 24.66% |
| 2012 | 186.53 Million CNY | -3.54% |
| 2011 | 193.39 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.41 Billion CNY | -6.35% |
| 2024 Q3 | 1.58 Billion CNY | -1.11% |
| 2024 Q2 | 1.6 Billion CNY | 13.69% |
| 2023 Q4 | 1.5 Billion CNY | -9.45% |
| 2023 Q3 | 1.66 Billion CNY | -5.16% |
| 2023 Q1 | 1.63 Billion CNY | -0.02% |
| 2023 FY | 1.5 Billion CNY | -7.62% |
| 2023 Q2 | 1.75 Billion CNY | 7.59% |
| 2022 Q4 | 1.63 Billion CNY | -6.43% |
| 2022 Q3 | 1.74 Billion CNY | -3.01% |
| 2022 Q2 | 1.79 Billion CNY | 6.36% |
| 2022 FY | 1.63 Billion CNY | -19.4% |
| 2022 Q1 | 1.69 Billion CNY | -16.51% |
| 2021 FY | 2.02 Billion CNY | -14.17% |
| 2021 Q4 | 2.02 Billion CNY | -10.63% |
| 2021 Q1 | 2.39 Billion CNY | 1.52% |
| 2021 Q2 | 2.44 Billion CNY | 2.25% |
| 2021 Q3 | 2.26 Billion CNY | -7.49% |
| 2020 Q4 | 2.35 Billion CNY | -2.69% |
| 2020 FY | 2.35 Billion CNY | 8.77% |
| 2020 Q2 | 2.45 Billion CNY | 10.69% |
| 2020 Q1 | 2.22 Billion CNY | 2.42% |
| 2020 Q3 | 2.42 Billion CNY | -1.4% |
| 2019 Q4 | 2.16 Billion CNY | 6.17% |
| 2019 Q3 | 2.04 Billion CNY | 4.45% |
| 2019 Q2 | 1.95 Billion CNY | 11.99% |
| 2019 Q1 | 1.74 Billion CNY | 3.26% |
| 2019 FY | 2.16 Billion CNY | 28.24% |
| 2018 FY | 1.69 Billion CNY | 74.36% |
| 2018 Q2 | 1.35 Billion CNY | 18.77% |
| 2018 Q1 | 1.14 Billion CNY | 17.86% |
| 2018 Q4 | 1.69 Billion CNY | 8.11% |
| 2018 Q3 | 1.56 Billion CNY | 15.22% |
| 2017 Q1 | 365.1 Million CNY | -12.02% |
| 2017 FY | 970.12 Million CNY | 133.76% |
| 2017 Q4 | 970.12 Million CNY | 16.99% |
| 2017 Q3 | 829.2 Million CNY | 37.85% |
| 2017 Q2 | 601.51 Million CNY | 64.75% |
| 2016 FY | 415 Million CNY | 11.65% |
| 2016 Q4 | 415 Million CNY | -7.15% |
| 2016 Q3 | 446.95 Million CNY | 10.24% |
| 2016 Q2 | 405.42 Million CNY | 38.49% |
| 2016 Q1 | 292.75 Million CNY | -21.24% |
| 2015 Q1 | 440.3 Million CNY | 3.78% |
| 2015 FY | 371.71 Million CNY | -12.39% |
| 2015 Q4 | 371.71 Million CNY | 2.06% |
| 2015 Q3 | 364.21 Million CNY | -24.37% |
| 2015 Q2 | 481.55 Million CNY | 9.37% |
| 2014 FY | 424.27 Million CNY | 82.46% |
| 2014 Q4 | 424.27 Million CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2013 FY | 232.53 Million CNY | 24.66% |
| 2012 FY | 186.53 Million CNY | -3.54% |
| 2011 FY | 193.39 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 8.02 Billion CNY | 81.209% |
| Hangzhou Tigermed Consulting Co., Ltd. | 5.22 Billion CNY | 71.167% |
| Dirui Industrial Co.,Ltd. | 1.26 Billion CNY | -19.418% |
| Beijing Strong Biotechnologies, Inc. | 1.45 Billion CNY | -3.685% |
| Medicalsystem Biotechnology Co., Ltd. | 772.59 Million CNY | -95.159% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.15 Billion CNY | -30.308% |
| Guangdong Hybribio Biotech Co.,Ltd. | 615.23 Million CNY | -145.075% |
| BGI Genomics Co., Ltd. | 3.6 Billion CNY | 58.221% |
| Amoy Diagnostics Co., Ltd. | 221.04 Million CNY | -582.122% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1 Billion CNY | -49.776% |